A series of trials in the adjuvant setting were conducted at approximately E75, demonstrating not only a good safety profile of the E75 peptide vaccine but also a superiority of immune response in BC patients with low HER2 expression than vaccinated patients with high levels of HER2 expression (101). The gene discussed is ERBB2; the disease is breast cancer.